Heterozygosity for mutations in the BRCA1 gene in humans confers high risk for developing breast cancer, but a biochemical basis for this phenotype has not yet been determined. Evidence has accumulated implicating BRCA1, in the maintenance of genomic integrity and the protection of cells against DNA double strand breaks (DSB). Here we present evidence that human cells heterozygous for BRCA1 mutations exhibit impaired DNA end-joining, which is the major DSB repair pathway in mammalian somatic cells. Using an in vivo host cell end-joining assay, we observed that the ®delity of DNA end-joining is strongly reduced in three BRCA1 +/7 cell lines in comparison to two control cell lines. Moreover, cell-free BRCA1 +/7 extracts are unable to promote accurate DNA end-joining in an in vitro reaction. The steady-state level of the wild type BRCA1 protein was signi®cantly lower than the 50% expected in BRCA1 +/7 cells and thus may underlie the observed endjoining defect. Together, these data strongly suggest that BRCA1 is necessary for faithful rejoining of broken DNA ends and that a single mutated BRCA1 allele is sucient to impair this process. This defect will compromise genomic stability in BRCA1 germ-line mutation carriers, triggering the genetic changes necessary for the initiation of neoplastic transformation.
Introduction
The inheritance of one defective copy of the breast cancer susceptibility gene, BRCA1, confers up to an 85% lifetime risk for developing breast and/or ovarian cancer (Hall et al., 1990; Miki et al., 1994) . Although the normal biological function of BRCA1 is not yet clearly understood, increasing evidence indicates that the presence of the wild-type protein is important for the maintenance of genomic integrity (for review, see Welcsh et al., 2000) . Biochemical and genetic studies suggest that the BRCA1 protein plays a role in protecting cells against double-strand breaks (DSB), which are one of the most deleterious DNA lesions.
There are two major DSB repair pathways in higher eukaryotes, homologous recombination and DNA endjoining (for review, see Haber, 2000) . The relative contribution of each of these pathways in mammalian cells seems to be a function of the stage of development: DNA end-joining is by far the major pathway in the adult animal and in dierentiated cells, while homologous recombination is prominent at the embryonic stage of early mouse development and in embryonic stem cells (Essers et al., 2000; Pluth et al., 2001) . Two aspects are important for each repair pathway: its eciency and its ®delity. The repair eciency re¯ects the capacity of cells to eliminate (in an error-free as well as in error-prone way) the lesions and is directly correlated to the ability of cells to survive after DNA damage. The repair ®delity re¯ects the capacity of cells to precisely restore the damaged DNA, without loss or gain of nucleotide sequences, which is an essential requirement for the faithful transmission of genetic information.
The co-localization in nuclear foci of the BRCA1 gene product with hRAD51 (Scully et al., 1997; Chen et al., 1998) , which is one of the key proteins involved in homologous recombination, suggested that BRCA1 may function in DSB repair via homologous recombination. A recent study, in which an unique viable BRCA1 homozygous mutant murine embryonic stem (ES) cell clone has been analysed and compared to corresponding heterozygous cells, reported reduced eciency of homologous recombination in response to a site-speci®c DSB (Moynahan et al., 1999) . Furthermore, the implication of BRCA1 in DNA end-joining has been suggested by a physical interaction between BRCA1 and hRAD50, both in vitro and in vivo (Zhong et al., 1999) . The complex that hRAD50 forms with hMRE11 and NBS1 is potentially im-plicated in both DNA end-joining and homologous recombination pathways (Haber, 2000) , where at least one function of this complex appears to be the sensing and/or signalling of a DSB to the check-point and repair machinery (Petrini, 1999) .
It has been reported that a lack of functional BRCA1 protein leads to a highly increased radiosensitivity and the accumulation of chromosomal abnormalities in mouse embryonic Brca1 7/7 ®broblasts and in a human tumor BRCA1 7/7 cell line (Shen et al., 1998; Foray et al., 1999; Scully et al., 1999) . Interestingly, the heterozygous BRCA1 +/7 human lymphoblasts show also an increased radiosensitivity, a higher level of radio-induced micronuclei and a lower DSB repair rate (Foray et al., 2000) . Radiosensitivity and enhanced micronuclei frequencies have also been reported in lymphocytes of 10 of 11 examined women BRCA1 carriers (Rothfub et al., 2000) . These observations lead to the question of whether the presence of a single mutated BRCA1 allele may aect the eciency and/or the ®delity of DSB repair pathway(s). Knowing that adult mammalian cells remove DSB predominantly by the DNA end-joining pathway, an important question is whether the DNA end-joining activity is intact in cells derived from BRCA1 mutation carriers.
To assess the capacity of BRCA1 +/7 cells to remove DSB via DNA end-joining, we analysed three lymphoblastoid cell lines derived from BRCA1 mutation carriers in parallel with two lymphoblastoid control cell lines derived from BRCA1 +/+ individuals. The data reported here present the ®rst demonstration that a single wild type BRCA1 allele is not sucient to permit an accurate repair via DNA end-joining. Using an extrachromosomal substrate carrying a de®ned DSB and in vivo host cell end-joining assay, we show that the ®delity of DNA end-joining is strongly aected in BRCA1 +/7 heterozygous cells. Moreover, cell-free extracts derived from BRCA1 heterozygous cell lines are inecient in promoting intermolecular in vitro endto-end joining. Additionally, we ®nd that the steadystate level of wild type BRCA1 protein is lower than the 50% expected in heterozygous individuals. Although the haplo-insuciency of the BRCA1
genotype cannot be excluded, the severely decreased level of wild type BRCA1 protein may underlie the dysfunctional DSB ends re-joining as well as the previously reported radiosensitivity and genomic instability in BRCA1 heterozygous cells.
Results
Assessing the fidelity of in vivo DNA end-joining in BRCA1 heterozygous cells
The eciency and the ®delity of in vivo DNA endjoining was assessed using a plasmid-based host cell end-joining assay (Escarceller et al., 1998) . A de®ned DSB, with either blunt or 5'-complementary termini, is introduced by the restriction endonucleases, EcoRV and EcoRI, respectively, which recognize a unique site within the pHRecCJ substrate ( Figure 1a ). The fate of these DSB were examined in three heterozygous lymphoblastoid cell lines, IC568, IC347 and IC1549, derived from BRCA1 germline mutation carriers (see Materials and methods), in parallel with two lymphoblastoid control cell lines, AHH-1 and HSC93, derived from healthy individuals.
In each experiment exponentially growing control and BRCA1 +/7 cells were transiently transfected in parallel and in duplicate with: (i) circular supercoiled plasmid, (ii) EcoRV-digested and (iii) EcoRI-digested plasmid. From the extracted plasmid DNA (Figure  1b) , we selected for analysis only DpnI-resistant substrates, since they have been replicated in human cells (see Materials and methods). Knowing that only recircularized plasmids can be replicated, this procedure assures that the recovered plasmids were repaired within the human cells. In the experiments described here, sequences homologous to the target gene, carried by pHRecCJ, are not available in human cells and thus the DSB introduced into pHRecCJ can only be repaired by DNA end-joining, which allows broken DNA ends to be rejoined in the absence of extensive homology.
To estimate the DSB end-joining eciency, DpnIdigested plasmids were electroporated into XL1-blue competent bacteria (Figure 1b) . The ratio between the number of bacterial colonies obtained after transformation with linearized versus circular plasmid is used to calculate the DSB end-joining eciency of each cell line. To examine the ®delity of the in vivo end-joining reaction, the recovered plasmids are digested with the restriction endonuclease that created the original DSB. Substrates that have been accurately rejoined (i.e. without loss of nucleotides) can be cleaved by the original restriction endonuclease and are classi®ed as error-free events, while those associated with deletions and/or insertions will be resistant to cleavage and are referred to as error-prone events.
More than 2500 plasmids recovered from control cell lines and from BRCA1 +/7 cells were analysed. Concerning the global DNA end-joining eciency, which includes both error-free and error-prone events, BRCA1 +/7 cells did not show a major defect (more than a 10-fold decrease) compared to control cells. In contrast, the ®delity of DNA end-joining was severely impaired in BRCA1 heterozygous cells, for DSB with either complementary (EcoRI-induced) or blunt (EcoRV-induced) termini (Figure 1c) . Indeed, the proportion of accurately rejoined substrates in control AHH-1 and HSC93 cells was 39 and 31% for EcoRVinduced DSB and 38 and 35% for EcoRI-induced DSB, respectively. In contrast, in BRCA1 heterozygous cells, the frequency of error-free rejoined plasmids was severely decreased (Figure 1c) . The DNA end-joining ®delity was most aected in the IC568 cell line, which carries a large deletion that includes exon 11. In these cells, only 1.8% of DSB with blunt termini and 4.7% of DSB with complementary termini were accurately rejoined. The IC347 and IC1549 cells were relatively less aected, 3.4 and 8.6% for EcoRV-induced DSB and 8.1 and 11.5% for EcoRI-induced DSB, respectively ( Figure 1c) .
The reduced accuracy of DNA end-joining in BRCA1 +/7 cells was accompanied by an increased level of error-prone end-joining, which is re¯ected by a much higher proportion of recombinants with deletions. Sequence analysis of 50 inaccurately rejoined plasmids recovered from IC568 cells indicated that the average size of deletions associated with these repair events was signi®cantly higher than that observed in control cells (data not shown). It should be noted that plasmid replication, which is required to detect repaired plasmids, may be slightly lower in BRCA1 heterozygous cells in comparison to control cells. However, in this case, the DNA end-joining ®delity should be even lower in BRCA1 heterozygous cells since, as we have recently shown, error-free events occur earlier and thus error-prone rejoined plasmids (late events) are more likely to remain unreplicated and therefore undetected (Smith et al., 2001) .
To investigate whether cell cycle kinetics may contribute to the observed end-joining defect we examined by¯ow cytometric analysis the cell cycle distribution, before and after transfection. The data indicates that the proportion of cells in G1, S and G2 phase was similar in control and BRCA1 heterozygous Figure 1 Assessing the eciency and ®delity of in vivo DNA end-joining in BRCA1 heterozygous cells. (a) pHRecCJ (6.2 kb), extrachromosomal substrate used to analyse in vivo host cell end-joining. ColE1 is the prokaryotic replication origin. Amp is the blactamase gene, conferring ampicilin resistance in E. Coli. The SV40 large T-antigen coding sequence and its replication origin (ori SV40) confer to pHRecCJ the capacity to replicate in human cells. The target is a modi®ed LacZ gene containing unique restriction sites for EcoRI and EcoRV. (b) Host cell end-joining assay. (c) The proportion (percent) of plasmids accurately (error-free) rejoined, recovered from control AHH-1 and HSC93 cells and from IC568, IC347 and IC1549 BRCA1 heterozygous cells. The input plasmid, linearized with EcoRV, contains a DSB with blunt termini and when linearized with EcoRI, a DSB with complementary terminicontaining 4 bp 3'-overhangs. The reported values are the average from six to eight independent transfections. For both DSB, 720 and 580 plasmids have been analysed respectively for control AHH-1 and HSC93 cells, and 510, 430 and 460 have been analysed respectively in IC568, IC347 and IC1549 BRCA1 heterozygous cells cells (data not shown). Thus, the impaired ®delity of the DSB end-joining is not due to dierences in distribution through the cell cycle compartments.
BRCA1
+/7 extracts are unable to promote in vitro end-joining reaction
We further examined the ability of BRCA1 heterozygous cells to carry out DNA end-joining by analysing the capacity of extracts derived from BRCA1 +/7 cells to catalyse in vitro end-joining reaction. We used an in vitro end-joining assay, developed by Baumann and West (1998) who demonstrated that extracts prepared from human cells eciently promote the conversion of linear DNA molecules into various mono-and multimeric products. This reaction is dependent on several keyproteins of the end-joining machinery including the Ku70/Ku86 heterodimer, DNA-PKcs, ligase IV and XRCC4 (Baumann and West, 1998 and data not shown). It is important to note that during this in vitro end-joining reaction only precise end-to-end joining was promoted (Baumann and West, 1998 ; and data not shown).
Linearized DNA substrates with de®ned end structures were generated using the pSJ substrate ( Figure  2a ) and restriction endonucleases that create blunt (HincII) or 4bp-complementary termini with either 5'-(HindIII) or 3'-(ApaI) overhangs. When the linear substrates were incubated with the extracts prepared from control cell lines, AHH-1 and HSC93, approximately 20 ± 35% of the input DNA molecules were rejoined during the 2 h incubation time ( Figure 2b , lanes 3 ± 6; Figure 2c , lanes 2 and 3; Figure 2d /2e, lanes 3 ± 10), which is consistent with data reported in previous studies (Baumann and West, 1998) The dierent DNA termini, blunt, complementary with 5' or with 3' overhangs were joined by control cell-free extracts with approximately the same eciency (Figure 2b ± e and data not shown).
Extracts prepared from all three BRCA1 +/7 cell lines had a signi®cantly lower end-joining activity in comparison to normal cells for all substrates examined (Figure 2b , lanes 7 ± 12). The similar amount of monomeric forms observed for all cell extracts, as well as the absence of smearing (i.e, degradation products), indicated that the low end-joining activity with BRCA1 +/7 cell free extracts was not due to the extensive degradation of the input plasmid DNA. However, since the in vitro end-joining reaction can promote only precise end-to-end joining (Baumann and West, 1998 ; and data not shown), the loss of even a few base pairs can strongly inhibit the rejoining reaction. Thus, we performed experiments in which the cell-free extracts were incubated with 5'-32 P-endlabeled HindIII-linearized pSJ plasmid. In this case, the degradation of even a single nucleotide from the labelled end will eliminate the signal. We observed that the monomeric form was almost completely lost when 5'-32 P-end-labelled HindIII-linearized substrate was incubated with two independent extract preparations from IC568 cells (Figure 2c, lanes 4 and 5) . Therefore, in vitro end-joining could not be accurately analysed in this cell line and IC568 cells have been discarded from further in vitro end-joining analysis. In contrast, for extracts derived from all other cell lines, the ends of the linearized plasmid remained intact (Figure 2c) . In other words, the inecient DNA endjoining by IC347 and IC1549 cell extracts was not due to even a single nucleotide degradation of DSB termini.
To investigate further whether the reduced amount of end-joining products observed with BRCA1 +/7 cellfree extracts was due to the incapacity to rejoin in vitro linearized substrates or to slower kinetics of the end-joining reaction, we examined the amount of joined products generated at dierent reaction times. Time course experiments with extracts prepared from control cell lines showed that the end-joining activity increased with the reaction time and, in most cases, reached a maximum at 2 h (rejoining of up to 40% of the input linear molecules) (Figure 2d ,e, lanes 3 ± 10). The BRCA1 +/7 cellular extracts appeared to follow the same kinetics, however, at each time point they showed a severely reduced level of end-joining activity (Figure 2d ,e, lanes 11 ± 18). The similar results were obtained with ApaI-digested plasmid (data not shown).
The in vitro experiments clearly show that BRCA1
cells are unable to promote error-free DNA end-joining reaction, a result which con®rms and extends the in vivo data of reduced end-joining ®delity.
The key components of the end-joining machinery are present in BRCA1 +/7 cell extracts It has been previously shown that ecient in vivo and in vitro DSB end-joining requires Ku70/Ku86 heterodimer, DNA-PKcs, Ligase IV, its protein cofactor XRCC4 and the complex RAD50/MRE11/NBS1 (for reviews, see Jeggo 1998; Karran 2000) . One possibility was that the inecient end-joining activity of BRCA1 +/7 extracts is due to altered amounts of components of the end-joining machinery. We therefore determined, using immunoblot analysis, the levels of DNA-PKcs, Ku86, XRCC4, as well as NBS1 and MRE11 in the cellular end-joining extracts. As shown in Figure 3a similar levels of these repair proteins were present in total extracts derived from normal and BRCA1 heterozygous cells.
Heterozygous cells display lower than expected levels of wild type BRCA1 protein
The same membranes, used for the detection of the above mentioned proteins, were assayed for the presence of wild type BRCA1 protein. Clearly, in comparison to normal cells, cell extracts prepared from BRCA1 +/7 cells displayed lower than the 50% expected level of the BRCA1 wild type protein ( Figure  3a) . Compared to the control cell lines AHH-1 and HSC93, the mean values of the observed densities for BRCA1 protein in IC568, IC347 and IC1549 hetero- +/7 cells were 31, 27 and 19%, respectively (Figure 3b ). Therefore, it is possible that the altered in vitro and in vivo end-joining activities in BRCA1 heterozygous cells are related to the reduced levels of wild type BRCA1 protein.
Discussion
The present work is the ®rst demonstration that heterozygocity for mutations in BRCA1 in human cells leads to a severely impaired ®delity of DSB endjoining. Using an extracromosomal recombination substrate containing a de®ned DSB, we show that the accuracy of in vivo end-to-end rejoining is strongly reduced in BRCA1 +/7 cells compared to controls. This result is further con®rmed by the observation that cellfree BRCA1 +/7 extracts are unable to promote an error-free in vitro Ku-dependent DNA end-joining reaction. This is true for all types of termini examined: blunt and complementary with 5' or 3' overhangs. We further demonstrate that the reduced eciency of accurate end-joining in BRCA1 +/7 cell extracts is not due to end-degradation, slower kinetics or the absence of key components (Ku86, DNA-PKcs, XRCC4, MRE11, NBS1) of the end-joining machinery. Therefore, the BRCA1 protein appears to play an important role in Ku-dependent error-free DNA end-joining and in a heterozygous state, the quantity of the wild type protein is not sucient to assure the ®delity of this major DSB repair pathway.
It should be pointed out that the overall in vivo DNA end-joining eciency (error-free and errorprone) was not substantially aected in BRCA1 +/7 cells. Therefore, approximately the same number of linearised substrates were rejoined in control and BRCA1 heterozygous cells. However, since the proportion of precisely recircularized in vivo plasmids in BRCA1 +/7 cells is extremely low, the high majority of repaired plasmids are error-prone rejoined and contain large deletions. In other words, error-prone DSB endjoining is substantially increased in BRCA1 heterozygous cells.
The impaired end-joining ®delity in BRCA1 heterozygous cells is consistent with previous studies showing that lymphoblasts or lymphocytes derived from BRCA1 mutation carriers show an increased genomic instability re¯ected by increased levels of micronuclei, spontaneously or in response to ionizing radiation (Foray et al., 1999; Rothfub et al., 2000) . If the presence of one BRCA1 mutated allele aects the normal cellular response to ionizing radiation, it can be expected that in BRCA1 7/7 cells the radiation sensitivity is ampli®ed. Indeed, with one exception (Wang et al., 2001) , several groups have shown that human breast cancer BRCA1 7/7 cells are hypersensitive to ionizing radiation and have a reduced global DSB-repair capability as measured by pulse-®eld gel electrophoresis (Abbott et al., 1999 , Foray et al., 1999 , Scully et al., 1999 . Interestingly, preliminary results, in our lab, with two breast tumor cell lines lacking BRCA1 wild type protein show a strong decrease of the in vivo DSB end-joining eciency (data not shown).
Recent elegant studies may provide a biochemical basis for the reduced end-joining ®delity that we observed in heterozygous BRCA1 +/7 cells. It has been demonstrated that recombinant human BRCA1 protein binds strongly to DNA and that this property probably plays an important role in targeting BRCA1 protein to sites of DNA damage (Paull et al., 2001) . It has been previously reported that soon after DSB formation, a phosphorylated form of H2AX (g-H2AX), a member of the histone H2A family, appears at sites of DSB (Rogakou et al., 1998 (Rogakou et al., , 1999 . This is followed by the recruitement of BRCA1 and, several hours later, RAD50 or RAD51 proteins join the nuclear foci created around the damaged DNA sites (Paull et al., 2000) . This suggests that BRCA1 acts upstream of the repair machinery and that it may in¯uence either homologous recombination or DNA end-joining. Even more interesting is the ®nding that the association of wild type BRCA1 with the RAD50/MRE11/NBS1 complex inhibits the exonuclease activity of this complex (Paull et al., 2001) . Such an inhibition will protect DNA ends from degradation and consequently will favour the faithful rejoining of broken DNA ends. The low level of wild type BRCA1 protein that we observe in heterozygous cells may not be sucient in preventing the degradation of broken DNA ends until the repair occurs. In these cells, the DSB termini may be joined after being partially degraded, thus explaining the strong decrease in faithful DNA end-joining that we observe. DNA end-joining as well as homologous recombination are involved in the elimination of DSB from the mammalian genome, however, the contribution of each seems to vary in function of cell type and the stage of development. It has been shown that mouse embryonic Brca1
®broblasts display a decreased level of homology-directed DSB repair in comparison to Brca1 +/7 cells (Moynahan et al., 1999) . If the data obtained in mouse embryonic cells are also valid for human somatic cells, then homologous recombination as well as DNA endjoining (data in the present study) are aected in BRCA1 de®cient cells.
It is of interest to point out that, unlike human BRCA1 heterozygotes, murine Brca1 heterozygous embryonic stem cells do not display increased radiosensitivity, chromosomal abnormalities or defects in DSB repair. Likewise, unlike human carriers, transgenic mice carrying a mutant Brca1 allele do not display an increased risk of tumour formation (for review, see Deng and Scott, 2000) . Whether this is related to the functional divergence of BRCA1 between humans and mice, the given type of mutation in the BRCA1 gene, or the genetic background, remains an open question.
BRCA1 appears to be a multifunctional protein. In addition to a defect in DSB repair, it has been reported that both mouse Brca1 7/7 stem cells, as well as human BRCA1 7/7 tumour cells, are de®cient in transcriptioncoupled repair of oxidative DNA damages (Goven et al., 1998; Abott et al., 1999; Le Page et al., 2000) . The recent identi®cation of the large multisubunit protein complex BASC (BRCA1-associated genome surveillance complex) may provide an explanation for the multifunctionality of BRCA1 . Interestingly, all members of the BASC complex identi®ed so far play a role in the recognition of abnormal DNA structures, such as DSB, mismatched DNA, stalled replication forks, Holliday junctions, telomere repeated sequences, etc. The presence of BRCA1 in the large BASC complex may indicate that BRCA1 acts as a coordinator between dierent competing DNA repair activities required for the maintenance of genomic integrity.
The second major ®nding in this study is that the steady-state level of wild type BRCA1 protein, analysed by immunoblotting, is 3 ± 5-fold lower in BRCA1 +/7 cellular extracts compared to those derived from control cells. This has been recently con®rmed by the analysis of two additional control cell lines and six lymphoblastoid cell lines carrying truncated mutations in one of the BRCA1 alleles (data not shown). Although it cannot be excluded that the presence of 50% of wild type BRCA1 protein levels is, by itself, not sucient to assure accurate DSB end-joining, we favour the hypothesis that the reduced ®delity of DNA end-joining in BRCA1 heterozygous lymphoblasts is related to the lower than expected levels of wild type BRCA1 protein.
What could account for the reduced level of protein derived from the single wild type BRCA1 allele? On one hand, it can be speculated that the absence of a functional allele leads to a down-regulation of the wild type allele. Whether this down regulation is transcriptional, translational or post-translational remains to be determined. A ®ne regulatory balance between BRCA1 transcription and proteolytic degradation has been recently proposed to be at the origin of the low steady-state level of BRCA1 protein observed in some human breast and prostate cancer cell lines (Blagosklonny et al., 1999) . On the other hand, although we are unable to detect the product of the mutant allele, its presence cannot be excluded. In this case, the mutant protein may actively contribute to the presence of decreased levels of wild type protein. This would imply that the BRCA1 protein acts either as a dimer or in aggregates with other proteins, and an association with the mutant protein would lead to rapid degradation (for review, see Wilkie, 1994) . Alternatively, the presence of the mutant for may lead to decreased intracellular stability of wild type BRCA1 without requiring the formation of an abnormal protein complex, as has been described for a growth hormone de®ciency case (Lee et al., 2000) . A recent study seems to be in favour with the ®rst hypothesis. Indeed, using biophysical and biochemical methodology, Yamane et al. (2000) have shown that the multimerization of BRCA1 occurs through the BRCTs motifs.
In summary, the data presented in this study strongly suggest a novel function for the BRCA1 gene: a role in the Ku-dependent error-free DSB end-joining pathway. Moreover, we have shown that the presence of one mutated BRCA1 allele is sucient to compromise the accurate repair of double strand breaks by DNA end-joining. Knowing that ionising irradiation and a number of anti-cancer drugs produce DSB, the data reported here may have important medical relevance for the follow up and management of BRCA1 mutation carriers.
Materials and methods

Cell lines
The lymphoblastoid cell lines designated IC568, IC347 and IC1549 have been established (GeÂ neÂ thon, France) from peripheral blood lymphocytes from BRCA1 mutation carriers (breast cancer patients at the Institut Curie, Paris, France). The mutant BRCA1 allele contains: (i) in IC568 cells, a large deletion of 23.8 kb encompassing exons 8 to 13 (Puget et al., 1999) ; (ii) in IC347 cells, a nonsense mutation in exon 13 (Stoppa-Lyonnet et al., 1997) ; and (iii) in IC1549 cells, a splice mutation at the donor site of intron 22 (StoppaLyonnet et al., unpublished data) .
The control lymphoblastoid cell lines, AHH-1 and HSC93, kindly provided respectively from Dr W Thilly, (MIT, Boston, MA, USA) and M. Buchwald (Hospital for Sick Children, Toronto, Canada), were derived from healthy donors. Cells were grown in suspension in RPMI 1640 medium supplemented with L-glutamine (2 mM), gentamycin (40 mg/ml) and 10% foetal calf serum (Gibco, BRL, France). Cell lines were maintained in exponential growth by daily dilution to 3610 5 cells per ml in humidi®ed 7% CO 2 atmosphere at 378C.
Host cell end-joining assay
The recombination substrate used in this study, pHRecCJ (Escarceller et al., 1998) , based on a pBluescript plasmid (Stratagene, CA, USA), contains the prokaryotic ColE1 replication origin and the b-lactamase gene (Figure 1a) . The plasmid is autonomously replicated in human cells due to the presence of the SV40 large T-antigen coding sequence and its replication origin. This substrate had been initially designed to examine V(D)J recombination activity in human cells (Smith et al., 1998) , for this reason it bears the target LacZ gene interrupted by a 376 bp fragment¯anked by a pair of the consensus V(D)J recombination signal sequences. Such a construction allows the detection and analysis of deletions up to 1800 bp. The same stock of linearized plasmid was used within the same experiment.
The plasmid pHRecCJ was linearized with restriction endonucleases EcoRV or EcoRI, which create blunt or complementary ends, respectively. Complete cleavage was veri®ed by agarose gel electrophoresis and by transformation into E. coli. The analysis by electron microscopy of linearized substrates demonstrated previously that the completeness of digestion was 599%. Transfections were performed by electroporation with a gene pulser (Bio-Rad, France) using 300 V and 950 mF. Exponentially growing cells (8 ± 10610 6 cells per experimental point) were washed, resuspended in 0.8 ml of phosphate buer HeBSCl (50 mM HEPES, 280 mM NaCl, 0.74 g/l KCl, 0.25 g/l Na 2 HPO 4 .2H2O, 2 g/l glucose, pH 7.4) and electroporated with pHRecCJ (1.25 mg per point). In each experiment, parallel transfections were performed using supercoiled and linearized plasmid. Immediately after transfection, cells were diluted into 10 ml of complete medium containing 15% foetal calf serum and incubated. The transfection eciency, measured by the use of a GFP-based plasmid (Stratagene, USA) was similar (12 ± 18%) for all cell lines studied.
Forty-eight hours after transfection the cells were harvested, washed twice with phosphate buer saline (PBS) and cell pellets were stored at 7208C. Plasmid DNA was extracted by an alkaline lysis procedure. Knowing that only recircularized substrates are eciently replicated, we eliminate, by digestion with DpnI, all plasmids that have not been replicated in the human cells. The plasmid pHRecCJ have more than 20 DpnI sites. Since DpnI cleaves bacterially methylated DNA and after replication in mammalian cells the DpnI sites are no longer methylated, this allowed to discard the unrepaired plasmids. Following dialysis against distilled water, plasmids were further electroporated into XL1-blue competent bacteria (Stratagene, CA, USA) and plated on LB agar plates containing ampicillin (100 mg/ml). The ratio between the number of bacterial colonies obtained after transformation with linearized versus circular plasmid provided a quanti®cation of plasmid survival, thereby re¯ecting the DSB endjoining capacity of each cell line.
Analysis of the recombinant plasmids
Small-scale plasmid DNA preparations were made from the bacterial ampicillin-resistant colonies. The analysis of restriction patterns after PvuII digestion allowed us to estimate the frequency of rearranged plasmids and the approximate size of deletions. The substrate with wild type restriction pro®le were further digested with the endonuclease used to induce DSB. This allowed us to discreminate the perfectly rejoined plasmid (in which EcoRV or EcoRI sites were reconstituted) from those carried small size deletions. The localization of the EcoRV and EcoRI sites into the modi®ed LacZ gene that is nonessential for plasmid maintenance permits the recovery of repair events that contain deletions of up to 1800 bp. Several substrates with deletions were sequenced using the Taq DyeDeoxy Terminator Cycle Sequencing Kit and an ABI 370A automated sequencer (Perkin Elmer CA, USA). Sequences of each rearranged substrate were compared with the wild-type plasmid using the ABI 373A Version Sequence Navigator software, (Applied Biosystems, CA, USA).
Preparation of cellular extracts.
The human cell-free extracts have been prepared following the procedure described by Baumann and West (1998) . Brie¯y, 1 to 2610 9 exponentially growing cells were washed three times with PBS, once in hypotonic lysis buer (HLB: 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 5 mM DTT) and cell pellets were resuspended in 2 vol of HLB. After incubation for 20 min on ice the cells were lysed by dounce homogenization adding progressively the protease inhibitors (phenylmethylsulfonyl 0.17 mg/ml; aprotinine, trypsin inhibitor 0.01 units/ml and 1 mg/ml each of pepstatin, chymostatin and leupeptin). Nuclei integrity was checked by Trypan blue staining. After 20 min on ice, 0.5 vol of high salt buer (HSB: 50 mM Tris-HCl, pH 7.5; 1 M KCl; 2 mM EDTA; 2 mM DTT) was added and the extract was centrifuged for 3 h at 42 000 r.p.m. in a Beckman SW50.1 rotor. The supernatant was recovered and dialyzed for 3 h against Ebuer (20 mM Tris-HCl, pH 8.0; 0.1 M KOAc; 20% (vol/vol) glycerol; 0.5 mM EDTA; 1 mM DTT), aliquots were fastfrozen and stored at 7708C. The extracts were quanti®ed with Bradford reagent and contained up to 20 mg/ml protein.
DNA substrates and in vitro end-joining reaction
The linear DNA molecules were prepared from pSJ plasmid (3.3 kb), which contains the prokaryotic ColE1 replication Deficient DNA end-joining in BRCA1 carriers C Baldeyron et al origin, the b-lactamase gene and the modi®ed LacZ gene, containing insertion of 376 bp (Figure 1b) . The pSJ is a derivative of pHRecSJ plasmid (6.5 kb), (Smith et al., 1998) , in which the SV40 large T-antigen coding sequence and its replication origin have been deleted. The plasmid was linearised with restriction endonucleases HincII to generated blunt-ended molecules or with HindIII and ApaI to create cohesive termini with 5' or 3'-overhangs, respectively. The in vitro end-joining assays were performed in a total reaction volume of 10 ml, in a buer containing 50 mM TrisHCl, pH 7.5, 60 mM KOAc, 0.5 mM Mg(OAc), 1 mM ATP, 1 mM DTT, and 0.1 mg/ml BSA. In a`standard' reaction the cell-free extract (approximately 90 mg protein) was incubated for 2 h with 30 ng of a linearized pSJ substrate. After deproteinization, 10% of the reaction products were loaded on 0.8% agarose gel. The reaction products were visualized by Southern transfer and hybridization with a 0.8 kb fragment from the LacZ gene, radioactively labeled with (a-32 P) dCTP (ICN, France) by the random prime labelling system (Rediprime II kit, Amersham Pharmacia Biotech, France). The reaction products were quanti®ed with the phosphoimager (BioRad, France).
In several experiments pSJ plasmid, linearized with HindIII, was dephosphorylated and subsequently radioactively 5'-end labeled with [g-32 P]ATP usingT4 polynucleotide kinase. The labelled plasmid DNA was puri®ed from unincorporated nucleotides using Qiaquick Nucleotide Removal Kit (Qiagen, France).
Immunoblotting
BRCA1 as well as the key proteins of the end-joining machinery, Ku86, DNA-PKcs, XRCC4, MRE11 and NBS1 were quanti®ed by Western blotting using the cellular endjoining extracts. Protein concentrations were quanti®ed by the Bradford method (BioRad). For each extract, 60 mg was run on a 6% SDS ± PAGE and blotted on Hybond P membranes (Amersham, Pharmacia, Biothec). The membranes were incubated with the primary antibody (murine monoclonal BRCA1 (Ab-1), rabbit polyclonal MRE11 (Ab-1) and NBS1 (Ab-1) (Oncogene Research Products, Cambridge, MA, USA), goat polyclonal DNA-PKcs (C-19), and XRCC4 (C-20) (Santa-Cruz Biotechnology, CA, USA) diluted in TBS-T (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20), washed extensively, and incubated with the appropriate horesradish peroxidase-linked secondary antibody (anti-mouse (Promega, France), anti-rabbit (Amersham Pharmacia Biotech,France), anti-goat (Santa-Cruz Biotechnology, CA, USA). Chemiluminescence was used for detection (ECLplus, Amersham-Pharmacia Biotech, France). The bands were quanti®ed using the software NIH image version 1.61.
